EBITDA: Income before interest, taxes, depreciation and amortization.
Acurx Pharmaceuticals, Inc. (ACXP) had EBITDA of $-1.72M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-1.68M |
|
-- |
|
-- |
|
$1.72M |
|
$-1.72M |
|
$0.04M |
|
$-1.68M |
|
$-1.68M |
|
$-1.68M |
|
$-1.68M |
|
$-1.68M |
|
$-1.68M |
|
$-1.72M |
|
|
EBITDA |
$-1.72M |
2.72M |
|
2.72M |
|
$-0.62 |
|
$-0.62 |
|
| Balance Sheet Financials | |
$9.54M |
|
-- |
|
-- |
|
$9.54M |
|
$2.53M |
|
-- |
|
-- |
|
$2.53M |
|
$7.01M |
|
$7.01M |
|
$7.01M |
|
3.39M |
|
| Cash Flow Statement Financials | |
$-1.41M |
|
-- |
|
$3.11M |
|
$7.56M |
|
$9.25M |
|
$1.70M |
|
$0.32M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.78 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-1.41M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-23.97% |
|
-23.97% |
|
-17.62% |
|
-23.97% |
|
$2.07 |
|
$-0.52 |
|
$-0.52 |
|